Tag

Depression

All articles tagged with #depression

health2 days ago•3 min saved

Synthetic DMT Trials Hint at Rapid Depression Relief With Guided Therapy

A phase II trial sponsored by Small Pharma (now Cybin UK) found a synthetic DMT formulation, delivered by injection with psychotherapeutic support, reduced depressive symptoms more than placebo after two weeks in 17 treated vs 17 controls. The study emphasizes the therapists’ role and notes the synthetic DMT yields a short, ~30-minute experience without vomiting (unlike traditional ayahuasca). While promising, the results are preliminary and require clinic-based administration, with broader context including FDA-approved ketamine therapy and ongoing psychedelics research.

via The Guardian|

#clinical-trials #depression #dmt

science3 days ago•25 min saved

Caffeine Linked to Reduced Brain Inflammation and Mood Benefits in Rodent Studies

A systematic review of 17 rodent experiments finds caffeine consistently lowers brain inflammation and improves anxiety- and depression-like behaviors, likely via adenosine receptor blockade, increased brain-derived neurotrophic factor, and reduced pro-inflammatory cytokines and oxidative stress; caffeine's effects are comparable to some antidepressants in animals, but most data come from adult male rodents with varied dosing, so human studies are needed to determine safety and applicability.

via PsyPost|

#anxiety #caffeine #depression

health6 days ago•6 min saved

Psilocybin-based therapy shows rapid relief in treatment-resistant depression, eyeing FDA approval

Compass Pathways reported two positive late-stage trials of a synthetic psilocybin treatment that rapidly reduces symptoms in patients with treatment-resistant depression, potentially becoming the first psychedelic medicine to gain full regulatory approval if the FDA approves it early next year.

via The Economist|

#compass-pathways #depression #fda

health8 days ago•7 min saved

One Short DMT Dose Sparks Lasting Depression Relief in Phase IIa Trial

A Phase IIa randomized trial found that a single 21.5 mg IV dose of DMT, producing a ~25-minute psychedelic experience, yielded rapid and durable antidepressant effects in adults with moderate-to-severe treatment-resistant depression—MADRS scores dropped more than placebo within one week and effects persisted up to six months for some participants; efficacy correlated with the intensity of the peak experience, and the brief session could be more cost-effective and easier to implement than longer psychedelic therapies, though larger trials are needed and use is restricted to controlled clinical settings with professional support.

via Neuroscience News|

#depression #dmt #health

mental-health8 days ago•27 min saved

Twenty-Minute Mindset Shift Turns Depression Into Strength, Fuels Goal Progress

A PsyPost report on three experiments with 748 adults shows a ~20-minute depression-reframing exercise—reading resilience stories and reflecting on personal strength—boosting self-efficacy and increasing two-week goal completion by about 49% versus a control. The approach also reduces perceived mismatch between illness and success, hinting at greater resilience, but relies on self-reported data and short follow-up and should complement, not replace, traditional treatments.

via PsyPost|

#depression #goal-pursuit #mental-health

biotech9 days ago•2 min saved

Compass’s psilocybin therapy advances toward FDA nod in severe depression

Compass Pathways reports positive Phase 3 results for its psilocybin-based treatment COMP360 in two trials for severe depression, suggesting potential FDA approval, though full data are needed to confirm the magnitude of benefit; if approved, it could become the first psilocybin product on the market, following Spravato (ketamine derivative).

via statnews.com|

#biotech #comp360 #compass-pathways

health9 days ago•17 min saved

Small DMT Trial Signals Potential Depression Treatment

A small UK Phase IIa randomized, placebo-controlled trial found that a single dose of DMT with psychotherapy significantly reduced depressive symptoms for up to three months (some participants up to six); 47% reached remission at three months. DMT appeared safe and well tolerated, but the study's small size means larger, longer trials are needed before it could become a standard depression treatment.

via Gizmodo|

#depression #dmt #health

health9 days ago•5 min saved

Single-Dose DMT Triggers Rapid Depression Relief in Early Trial

In a double-blind, placebo-controlled trial with 34 adults suffering from treatment-resistant major depressive disorder, a single intravenous dose of DMT with psychotherapeutic support produced a rapid and meaningful reduction in depressive symptoms within a week, with effects lasting up to three months (some in remission for six months); the dose appeared safe with mostly mild side effects, though blinding was challenged by noticeable psychedelic effects and the small sample size calls for larger trials.

via ScienceAlert|

#clinical-trial #depression #dmt

health10 days ago•5 min saved

Late-Life Depression Linked to Early Parkinson's or Lewy Body Dementia, Study Finds

A Danish study following 17,711 people over 12 years found that depression is more common years before a diagnosis of Parkinson's disease or Lewy body dementia, with rates rising about eight years prior and remaining elevated after diagnosis, strongest for Lewy body dementia. By comparing with rheumatoid arthritis, chronic kidney disease, and osteoporosis, researchers suggest the link isn’t solely due to disability. The study shows association, not causation, and supports screening older adults with new or late-onset depression for early neurodegenerative signs to enable earlier care and research.

via ScienceAlert|

#depression #early-detection #health

neuroimaging11 days ago•20 min saved

Polygenic anhedonia risk linked to altered reward-brain activity

A German neuroimaging study found that individuals with higher polygenic risk scores for anhedonia show distinct brain activity during a monetary incentive delay task: they exhibit decreased activation in the bilateral putamen and left middle frontal gyrus during reward anticipation and reduced right caudate activity during reward feedback. Higher risk is also associated with lower activity in the left middle frontal gyrus when anticipating losses and during salience processing, while there is heightened activity in the bilateral putamen and right caudate during loss feedback. The results highlight the involvement of striatal and prefrontal circuits in genetic risk for anhedonia, though replication and further research are needed.

via PsyPost|

#anhedonia #depression #fmri

health12 days ago•3 min saved

Fifteen-year-old exam stress linked to lasting mental health risks into adulthood

A UK study of nearly 5,000 youths found that higher academic pressure at age 15 predicts more depression and self-harm into the mid-20s, with each extra point of pressure raising the risk of depression by 25% and self-harm by 8% by age 16, and increasing the likelihood of ever attempting suicide by 16% by age 24; researchers urge schools to reduce high-stakes testing and implement whole-school, social-emotional learning strategies, while families are encouraged to support healthy routines and limit pressure.

via The Guardian|

#academic-pressure #adolescent-mental-health #depression

science17 days ago•3 min saved

Five Sleep Subtypes Reveal Diverse Health and Lifestyle Patterns

A new study identifies five sleep subtypes (two early birds and three night owls) linked to distinct health and lifestyle patterns across UK Biobank adults and US teens, ranging from fewer health problems to depression, smoking, and higher cardiovascular risk, suggesting sleep timing profiling could inform personalized schedules and mental-health support.

via ScienceAlert|

#cardiovascular #chronotypes #depression

science20 days ago•5 min saved

Bone-Brain Axis Sparks a Two-Way Link Between Mood and Bone Health

A new review argues that the bone-brain axis is a real physiological network in which bone-derived signals such as osteocalcin and osteopontin can affect brain function and mood, while depression and stress hormones can contribute to bone loss; recognizing this two-way communication could lead to integrated treatments (including exercise, neuromodulation, or bone-targeted therapies) and more targeted clinical research.

via ScienceAlert|

#bone-brain-axis #depression #osteocalcin

health21 days ago•264 min saved

Reducing Ultra-Processed Foods May Benefit Mood, Study Finds

A scoping review of 123 studies links higher intake of ultra-processed foods with more depressive symptoms and other mental-health issues, potentially through brain lipid disruption and increased inflammation. The findings suggest that shifting toward whole, nutrient-dense foods and healthier fats may support better mood and emotional well-being, with practical swaps like choosing fruits, vegetables, nuts, and water or coffee with less sugar over sugary drinks and fried snacks.

via AOL.com|

#depression #diet #health

health23 days ago•12 min saved

The Elusive Fit: Why Antidepressants Don’t Work for Everyone

Antidepressants have helped some people for decades, but research shows they often provide only modest relief overall, with no reliable way to predict who will benefit. The history traces from iproniazid and imipramine to SSRIs and beyond, while meta-analyses indicate small improvements over placebo and low remission rates for many drugs. Ketamine offers rapid relief for some with treatment-resistant depression, challenging the idea that depression is a simple chemical imbalance. Precision psychiatry aims to tailor treatments via blood tests and genetic or neural markers, but this approach is still years away from routine practice. The field continues to wrestle with what depression actually is and how to best help the millions affected.

via The Dispatch|

#antidepressants #depression #health